Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Abstract EN

Objective.

To compare the modifications in lipids between patients with rheumatoid arthritis (RA) receiving etanercept plus methotrexate (ETA + MTX) versus methotrexate (MTX) and their relationship with serum levels of tumor necrosis factor-alpha (TNF-α).

Methods.

In an observational cohort study, we compared changes in lipid levels in patients receiving ETA + MTX versus MTX in RA.

These groups were assessed at baseline and at 4 and 24 weeks, measuring clinical outcomes, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, and TNF-α.

Results.

Baseline values for lipid levels were similar in both groups.

HDL-C levels increased significantly only in the ETA + MTX group (from 45.5 to 50.0 mg/dL at 4 weeks, a 10.2% increase, P<0.001, and to 56.0 mg/dL at 24 weeks, a 25.1% increase, P<0.001), while other lipids underwent no significant changes.

ETA + MTX also exhibited a significant increase in TNF-α (44.8 pg/mL at baseline versus 281.4 pg/mL at 24 weeks, P<0.001).

The MTX group had no significant changes in lipids or TNF-α.

Significant differences in HDL-C between groups were observed at 24 weeks (P=0.04) and also in TNF-α (P=0.01).

Conclusion.

HDL-C levels increased significantly following treatment with ETA + MTX, without a relationship with decrease of TNF-α.